Effect of rosiglitazone on inflammatory mediators in type 2 diabetes

Abstract

Type 2 diabetes is a heterogenous disorder involving impairment of both insulin secretion and insulin action. Inflammation is predominantly seen in type 2 diabetes. The effect of rosiglitazone on inflammatory mediators was analysed in the present study. The study groups consisted of 220 type 2 diabetic patients (110 Males, 110 Females) and 220 age and sex matched rosiglitazone treated type 2 diabetic subjects (110 Males, 110 Females). The values of C-reactive protein (CRP), Complement 3 (C3), ceruloplasmin, cortisol, alpha 1 antitrypsin and haptoglobin were found to be significantly decreased by rosiglitazone when compared to type 2 diabetic subjects. The levels of tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and adiponectin were found to be remarkably reduced in rosiglitazone treated type 2 diabetic subjects as compared to type 2 diabetic patients. Hence rosiglitazone therapy serves as an effective approach in restoring immune status in type 2 diabetes mellitus.